Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Blood (2024) 144 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2024-203422

Published: 2024

Journal Articles

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 4528.

https://doi.org/10.1182/blood-2024-205232

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Yanliang Bai, Yunya Luo, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2024-202430

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Lei Ju, Xingli Zhao, Xiaohui Suo, ZePing Zhou, Yanliang Bai, Yunya Luo, Sifeng Gao, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Yaxian Tan, Guanchen Bai, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 1505.

https://doi.org/10.1182/blood-2024-202971

Published: 2024

Journal Articles

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Wenbing Duan, Chunkang Chang, Zhiguo Wang, Hongbing Ma, Min Ouyang, Xingli Zhao, Lifan Tu, Guodong Wu, Xunqiang Wang, Xiao Jun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 1504.

https://doi.org/10.1182/blood-2024-204972

Published: 2024

Journal Articles

Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-Risk AML

Shulian Chen, Xiaoyu Zhang, Yi He, Sizhou Feng, Mingzhe Han, Xingli Zhao, Jie Bai, Lijuan Li, Zhihua Zhang, Wang Ying, Jianxiang Wang, Weihua Zhai, Erlie Jiang

Blood (2024) 144 (Supplement 1): 6054.

https://doi.org/10.1182/blood-2024-202404

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2024-202495

Published: 2024

Journal Articles

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2024-198844

Published: 2024

Journal Articles

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Zepin Zhou, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Zeyan Shi, Yunya Luo, Yaxian Tan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Heng Li, Weihua Zhao, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2023) 142 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2023-179275

Published: 2023

Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)

Hongyan Tong, Sujun Gao, Wei Yang, Junmin Li, Qingsong Yin, Xingli Zhao, Xiaojing Yan, Sanfang Tu, Fei Li, Haiping Yang, Ronghua Hu, Shaoyuan Wang, Zheng Dong, Yixuan Yang, Zhenjiu Wang, Qiying Lu, Wenzhi Tian, Zhijian Xiao, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2023-181501

Published: 2023

Journal Articles

The Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for Autologous-HSCT in Low-Risk and Intermediate-Risk AML Patients

Weihua Zhai, Shulian Chen, Xiaoyu Zhang, Yi He, Sizhou Feng, Mingzhe Han, Xingli Zhao, Jie Bai, Lijuan Li, Zhihua Zhang, Ying Wang, Erlie Jiang, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2023-180077

Published: 2023

Journal Articles

Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Blood (2023) 142 (Supplement 1): 969.

https://doi.org/10.1182/blood-2023-179205

Published: 2023

Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Blood (2023) 142 (Supplement 1): 320.

https://doi.org/10.1182/blood-2023-174420

Published: 2023

Journal Articles

Three-Day Decitabine Combined with Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML

Xiaohui Suo, Guanchen Bai, Xingli Zhao, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Xinxiao Lu, Linyu Yuan, Yingchang Mi, Kaiqi Liu

Blood (2023) 142 (Supplement 1): 5942.

https://doi.org/10.1182/blood-2023-181804

Published: 2023

Journal Articles

The Impact of Allogeneic Hematopoietic Stem-Cell Transplantation on Outcome of the Patients with Intermediate-Risk Acute Myeloid Leukemia

Ying Wang, MD, Hui Wei, MD PhD, Dong Lin, MD PhD, Chunlin Zhou, MD PhD, Bingcheng Liu, Shaowei Qiu, Benfa Gong, Guangji Zhang, Kaiqi Liu, Shuning Wei, Yuntao Liu, Xiaoyuan Gong, MD, Xingli Zhao, Yan Li, MD, Runxia Gu, MD PhD, Yingchang Mi, MD, PhD, Jianxiang Wang, MD

Blood (2016) 128 (22): 4015.

https://doi.org/10.1182/blood.V128.22.4015.4015

Published: 2016

Journal Articles

Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia

Qifang Zhang, Dewan Md Sakib Hossain, Priyanka Duttagupta, Dayson Moreira, Xingli Zhao, Haejung Won, Ralf Buettner, Sergey Nechaev, Marcin Majka, Bin Zhang, Qi Cai, Piotr Swiderski, Ya-Huei Kuo, Stephen Forman, Guido Marcucci, Marcin Kortylewski

Blood (2016) 127 (13): 1687–1700.

https://doi.org/10.1182/blood-2015-08-665604

Published: 2016

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-Risk AML

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)

The Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for Autologous-HSCT in Low-Risk and Intermediate-Risk AML Patients

Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Three-Day Decitabine Combined with Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML

The Impact of Allogeneic Hematopoietic Stem-Cell Transplantation on Outcome of the Patients with Intermediate-Risk Acute Myeloid Leukemia

Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only